Zondan Partners with Masimo to Incorporate Signal Extraction Technology® and rainbow® Across Entire Portfolio of Patient Monitors

SHENZHEN, China and IRVINE, Calif., Aug. 6, 2012 /PRNewswire/ -- Zondan and Masimo (NASDAQ: MASI) jointly announced today a new technology integration strategy that will make Masimo SET^® and Masimo rainbow^® SET Pulse CO-Oximetry™ a fundamental offering in Zondan's comprehensive multiparameter  monitoring product line-up – providing clinicians innovative, noninvasive, continuous measurements and patient monitoring capabilities to detect potentially life-threatening conditions. 

"By incorporating SET^® and rainbow^® into our products, we believe our combined technology offerings will provide caregivers across the patient-care continuum with the most advanced clinical assessment tools available," said Feng Li, General Manager of Zondan. "This partnership with Masimo reinforces our corporate philosophy and commitment to 'Improving Health Through Technology.'"

In 2011, Zondan focused its engineering design and development on the N Series of patient monitors, with the vision that each patient care or critical care setting in a hospital is unique and specialized. The N Series is designed to address a range of applications in multiple specialty care areas, such as the general ward, EMS/transport, NICU, ICU/CCUs, and operating rooms. Zondan developed its own core technology and clinical assessment tools to meet the patient monitoring challenges found in these environments. For example, in the NICU, the N1 monitor utilizes Zondan's neonatal-specific algorithms for event detection, alarm management, and its unique apnea analysis diagram to guard the precious lives of infants. With the addition of Masimo's renowned Signal Extraction Technology (SET^®) – recognized for its performance in measuring through motion and low perfusion, its ability to help clinicians reduce retinopathy of prematurity,¹ and detect critical congenital heart disease in newborns² – the N1 monitor brings newborn monitoring and assessment to an entirely new level of accuracy and performance.   

To date, more than 100 independent and objective studies have shown that Masimo SET^® outperforms all other pulse oximetry technologies, even under the most challenging conditions of patient motion and low peripheral perfusion. Utilizing patented signal processing technologies, including parallel engines and adaptive filters, Masimo SET^® delivers accurate measurements of a patient's true oxygenation status when conventional pulse oximetry technologies don't – reducing false patient monitor alarms by over 95% (sensitivity) and expanding true alarm detection to over 97% (specificity).³

In higher acuity patient care areas such as the ICU/CCU or OR, Zondan patient monitors will incorporate the rainbow^® technology, including noninvasive and continuous measurements for total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and rainbow® Acoustic Monitoring™ (RAM™), in addition to SET^®.

Li stated, "With limited access to healthcare in parts of China, and advanced monitoring technologies in short supply within many healthcare facilities, the Chinese government is investing heavily in innovative companies and technologies that will advance access to affordable, high quality patient care. Partnering with Masimo, we see a huge potential to address this unmet need." 

"Masimo's mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications," said Rick Fishel, Masimo's President of Worldwide OEM Business & Business Development. "Zondan has a shared vision for bringing innovative, noninvasive, real-time technologies to the bedside so that caregivers may make informed clinical decisions earlier. We are happy that SET^® and rainbow^® Pulse CO-Oximetry™ platforms are a key component in Zondan's new N Series of patient monitors."

1 Chow L.C., Wright K.W., Sola A.; CSMC Oxygen Administration Study Group. "Can Changes in Clinical Practice Decrease the Incidence of Severe Retinopathy of Prematurity in Very Low Birth Weight Infants?" Pediatrics. 2003 Feb;111(2):339-45.
2 de Wahl Granelli A, Wennergren M, Sandberg K, et al. Impact of pulse oximetry screening on detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ 2009; 338: a3037.
3 Shah N., Estanol L. "An Evaluation of Three New Generation Pulse Oximeters during Motion & Low Perfusion in Volunteers." Anesthesiology 2006; 102: S-75.

About Shenzhen Hexin Zondan Medical Equipment Co., Ltd
Established in 2002, Zondan is one of China's leading developers and manufacturers of multi-parameter patient monitor. Our products provide a wide range of applications in specialty such as internal medicine, surgery, operation rooms, ICU/CCU, pediatric, emergency services and we are the first to offer professional monitoring solutions that are tailored to clinical specialty departments in the country. Over the years, Zondan's dedication in development and technological progress take the company to among China's leading roles in the field of multi-parameter patient monitor supplier. Holding with proprietary patented core technology, Zondan continuously focuses in research, development and innovation to bring quality products with the best cost performance to our customers around the globe. Additional information about Zondan and its products is available on the company's website: www.zondan.com.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms all other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, the company introduced Masimo Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET® and Masimo rainbow SET® technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to:  risks related to our assumptions of the repeatability of clinical results obtained using the new Masimo Pronto-7 and noninvasive sensor sizes, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO₂, pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine  are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

SOURCE Masimo